# Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer

Source: https://onco.cc/trials/nct05972655/  
OnCo record `nct05972655` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of capecitabine and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Sir Run Run Shaw Hospital, now recruiting.

## Summary

Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer is a phase 2, interventional study registered as NCT05972655 by Sir Run Run Shaw Hospital, with a registry enrolment figure of 32 participants, started 2023-08-02 and due to reach its primary completion in 2024-08-20. Interventions recorded: Modified short-course radiotherapy; PD-1 antibody; Capecitabine; Oxaliplatin. Conditions listed: Low Rectal Cancer. Primary outcome: Pathological complete response (pCR) rate. Colorectal eligibility wording from the registry: "Patients diagnosed with low rectal cancer within 10 cm from the lower edge of the tumor to the anal verge by pelvic MRI and anorectoscopy, the clinical stage is cT2N+M0/cT3-4aN0/+M0, the lymph nodes are limited to the mesorectum, the circumferential resection margin is negative". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: mRCAT
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05972655
- Phase: 2
- Setting: Modified Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Locally Advanced of Middle and Low Rectal Cancer (mRCAT): An Open-label, Single-arm, Prospective Multicenter Clinical Trial
- Sponsor: Sir Run Run Shaw Hospital
- Enrolled: 32

## Sources

- ClinicalTrials.gov NCT05972655: https://clinicaltrials.gov/study/NCT05972655

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05972655.json